At a glance

Type

Medicine / medicine family

Regulatory context

United States: this overview describes the cited product-specific prescribing information. It is not a statement of Thai approval or current commercial availability.

Evidence

Evidence is strongest for the named medicines, studied populations and measured outcomes. Brand, formulation, indication and jurisdiction remain essential distinctions.

What it is

Tirzepatide is the active molecule in Mounjaro and Zepbound, but their prescribing information answers different clinical questions. Mounjaro addresses type 2 diabetes. Zepbound covers chronic weight management in eligible adults and moderate-to-severe obstructive sleep apnoea in adults with obesity. Neither brand name should be used as shorthand for an unspecified compounded preparation. [1] [2]

What the research shows

SURMOUNT-1 randomly assigned 2,539 adults with obesity, or overweight with a weight-related complication, without diabetes, to tirzepatide or placebo for 72 weeks. Average weight reductions across the three trial groups were 15.0%, 19.5% and 20.9%, compared with 3.1% with placebo. These are group averages under trial conditions, not a forecast for an individual. The study was funded by Eli Lilly. [3]

What longer follow-up adds

A later SURMOUNT-1 report followed the 1,032 participants who also had prediabetes over a longer treatment period and assessed progression to type 2 diabetes. That is a defined subgroup and outcome, rather than evidence for universal diabetes prevention or use in people at normal weight. [4]

What remains uncertain

Results from different trials cannot be used as a head-to-head ranking without accounting for population, follow-up, treatment adherence and analysis method. A body-weight outcome also does not answer every question about long-term health, tolerability or what happens after treatment stops. The complete study and the appropriate product label should inform the discussion. [3] [4]

Formulation and clinical context

In the United States, compounded drugs do not undergo the same FDA premarket approval review as approved medicines. A shared ingredient name does not make two preparations interchangeable. Ask which exact product, formulation and indication are being considered, and what authorisation applies where care is delivered. [5]

Questions for your doctor

Which indication applies to me? How do my medicines, gastrointestinal history, pregnancy plans and relevant family history affect the decision? What benefit will we measure, what monitoring is needed, and when would treatment be reconsidered? These questions support a consultation; this guide does not set a dose or treatment plan. [2]

Safety and clinical context

The Zepbound label warns about thyroid C-cell tumours in rats, with uncertain human relevance, and contraindicates use with a personal or family history of medullary thyroid carcinoma or MEN2. Gastrointestinal effects are common; pancreatitis, gallbladder disease, dehydration-related kidney injury, severe allergy and hypoglycaemia with some diabetes medicines require attention. Pregnancy and planned procedures need discussion with the prescriber. [2]

Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.